Pharmacology/Pharmaceutical Industry
Randomized Trial: High-Dose Vitamin D Supplementation Does Not Improve Bone Health and May Result in Lower Bone Mineral Density
28 Aug, 2019 | 02:33h | UTCEffect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial – JAMA (free for a limited period)
Commentary: High-Dose Vitamin D Might Reduce Bone Mineral Density – NEJM Journal Watch (free)
Related Commentary on Twitter
Vitamin D study: "Among healthy adults, supplementation with higher doses of vitamin D did not improve bone health." https://t.co/pugZ4Ilxke via @JAMA_current @SMCCanada cc @DietitiansCAN @medmyths @joansalgeblake @picardonhealth @CBCHealth pic.twitter.com/4BocJC1EeT
— Timothy Caulfield (@CaulfieldTim) August 27, 2019
Cohort Study: How Many Older Adults Receive Drugs of Questionable Clinical Benefit Near the End of Life?
28 Aug, 2019 | 02:26h | UTCRelated Studies: Use of Medications of Questionable Benefit at the End of Life (link to abstract and commentaries) AND Preventive Drugs in the Last Year of Life of Older Adults with Cancer: Is There Room for Deprescribing? (link to abstract and commentary)
Cardiovascular Toxicity of Immune Checkpoint Inhibitors in Cancer Patients
28 Aug, 2019 | 02:11h | UTCRelated: Immune Checkpoint Inhibitor Toxicities (free guidelines and reviews on the subject)
Meta-Analysis: Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors for the Treatment of Melanoma
28 Aug, 2019 | 02:11h | UTCCommentary: Risk of Cardiovascular Adverse Events in Patients With Melanoma Treated With Combined BRAF and MEK Inhibition vs BRAF Inhibition Alone – The ASCO Post (free)
Study: Acute Gallbladder or Biliary Disease More Common in Patients Using Liraglutide
27 Aug, 2019 | 00:31h | UTCEffects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial – Diabetes Care (free PDF for a limited period)
Commentary: Gallbladder, Biliary Tract Events Increased With Liraglutide – Medscape (free registration required)
[Abstract Only] Observational Study Suggests Women with Heart Failure May Need Lower Doses of ACE Inhibitors or ARBs and β blockers than Men
25 Aug, 2019 | 21:31h | UTCIdentifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study – The Lancet (link to abstract – $ for full-text)
Related Commentary on Twitter
BIOSTAT-CHF trial (n=1,710) lowest mortality rates occurred at 100% of the recommended dose of ACEIs & β blockers for men, but women showed significant lower risk at 50% of the recommended doses with no further improvement at higher dose levels.https://t.co/OL2PIPl1aF
— Dr Rani Khatib FESC (@DrRaniKhatib) August 23, 2019
[Abstract Only] Randomized Trial: Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases
23 Aug, 2019 | 08:48h | UTCEffectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial – The Lancet (link to abstract – $ for full-text)
Commentaries: 4-Drug Polypill Cuts CV Risk – NEJM Journal Watch (free) AND Four-in-one pill prevents third of heart problems – BBC (free)
Related: Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology – Global Heart (free) AND Perspective: The Polypill and the Long Journey to Major Impact (opinion and reviews on the subject) AND Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care (free commentaries)
Related Commentary on Twitter
NEW Research—Large five-year randomised trial supports use of #polypill to prevent #CVD: finding from PolyIran, a pragmatic, cluster-randomised trial #LancetCardiology #ESCCongress https://t.co/YtU4MBPWom pic.twitter.com/GocADDE7Kv
— The Lancet (@TheLancet) August 23, 2019
Clinicians’ Guide to Cannabidiol and Hemp Oils
23 Aug, 2019 | 08:40h | UTCClinicians’ Guide to Cannabidiol and Hemp Oils – Mayo Clinic Proceedings (free)
Related: Guideline for Prescribing Medical Cannabinoids in Primary Care (free)
Redefining Medication Management in Dialysis: A Kidney Pharmacy Quality Pyramid
23 Aug, 2019 | 08:38h | UTCRedefining Medication Management in Dialysis: A Kidney Pharmacy Quality Pyramid – Kidney Medicine (free)
Related: Drug Management in the Elderly Adult With Chronic Kidney Disease: A Review for the Primary Care Physician – Mayo Clinic Proceedings (free) AND Medication Reconciliation and Therapy Management in Dialysis-Dependent Patients: Need for a Systematic Approach – Clinical Journal of the American Society of Nephrology (free)
Study: Billions Could be Saved if Older Generics Were Prescribed
21 Aug, 2019 | 08:32h | UTCCommentary: Prescribing older generics could’ve saved Medicare $17.7B, study finds – Becker’s Hospital Review (free)
Related Study: Potential Savings from Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers (no abstract – $ for full-text)
AHA Scientific Advisory: Omega-3 Fatty Acids for the Management of Hypertriglyceridemia
20 Aug, 2019 | 08:57h | UTCNews Release: Prescription omega-3 fatty acid medications effectively lower high triglycerides – American Heart Association (free)
Related: Omega-3 Supplements Do Not Reduce the Risk of Cancer or Cardiovascular Disease (randomized trial and systematic reviews on the subject)
Cohort Study: Intensifying Antihypertensive Medication Regimens Among Older Adults at Hospital Discharge Linked to Worse Outcomes
20 Aug, 2019 | 08:35h | UTCClinical Outcomes After Intensifying Antihypertensive Medication Regimens Among Older Adults at Hospital Discharge – JAMA Internal Medicine (free for a limited period)
Commentary: Intensifying Antihypertensives at Discharge Tied to Adverse Events – NEJM Journal Watch (free)
Related Study: Overtreatment of Blood Pressure Common at Hospital Discharge (free)
Promising new Tuberculosis Drug Approved, But Will it be Affordable?
18 Aug, 2019 | 22:00h | UTCOriginal News Release: FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs – U.S. Food & Drug Administration (free)
See also: New Drug Could Be Game Changer For Drug-Resistant TB. But A Question Looms – NPR (free) AND Treatment for extreme drug-resistant tuberculosis wins US government approval – Nature (free) AND Scientists Discover New Cure for the Deadliest Strain of Tuberculosis – The New York Times (10 articles per month are free) AND U.S. FDA approves TB Alliance’s treatment for drug-resistant tuberculosis – Reuters (free)
Randomized Trial: Bismuth Subsalicylate Reduces Antibiotic Use Among Adult Outpatients With Diarrhea
18 Aug, 2019 | 21:59h | UTC
Meta-Analysis: Association Between Vitamin D Supplementation and Mortality
16 Aug, 2019 | 07:59h | UTCRelated: Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention (link to abstract and commentary) AND NICE Guideline: Vitamin D Supplementation (free)
Vitamin D supplementation was not associated with all-cause mortality, cardiovascular mortality, or non-cancer, non-cardiovascular mortality. However, Vitamin D supplementation statistically significantly reduced the risk of cancer death by 16%.
Related Commentary on Twitter
Vitamin D supplementation alone was not associated with all cause mortality in adults compared with placebo or no treatment. However, it was associated with a reduced risk of cancer mortality by 16%, finds #BMJResearch https://t.co/jc4Tdxl6Bb
— The BMJ (@bmj_latest) August 12, 2019
Update on the Contraceptive Contraindications
14 Aug, 2019 | 08:32h | UTCRelated Guidelines: WHO Medical eligibility criteria for contraceptive use (free PDF) AND US Medical Eligibility Criteria for Contraceptive Use (free) AND UK Medical Eligibility Criteria for Contraceptive Use (free)
Study: Androgen-deprivation Therapies May Increase the Risk of QT Prolongation and Arrhythmias
13 Aug, 2019 | 01:26h | UTCAndrogenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes – Circulation (free PDF for a limited period)
Commentaries: Androgen-Deprivation Therapy May Increase Risk for QT Prolongation and Torsades de Pointes – The ASCO Post (free) AND ADT Linked to Arrhythmias, QT Prolongation – MedPage Today (free registration required)
Meta-Analysis: Medications that Reduce or Increase the Risk of New Onset Diabetes
11 Aug, 2019 | 22:24h | UTC“α-Glucosidase inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, metformin, orlistat, phentermine/topiramate, and pioglitazone significantly reduced the risk of biochemical conversion to T2DM, whereas statins and nateglinide increased the risk”
ASCO Guideline: Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
7 Aug, 2019 | 08:34h | UTCSee also: Summary of Recommendations (free PDF) AND Visual Abstract (free PDF)
[Abstract Only] Study: Metformin Use Linked to Reduced Risk for Cardiovascular Death and All-cause Mortality
7 Aug, 2019 | 07:54h | UTCMetformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial – Circulation (link to abstract – $ for full-text)
Commentaries: Metformin Use and CV Outcomes Among Diabetes Patients – American College of Cardiology (free) AND Support for metformin cardioprotective effect – Medicine Matters (free) AND Metformin Use Associated With Lower Death Risk in Type 2 Diabetes – Renal & Urology News (free)
Cohort Study: Perioperative Management of Patients with Atrial Fibrillation Receiving a Direct Oral Anticoagulant
6 Aug, 2019 | 08:10h | UTCPerioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant – JAMA Internal Medicine (free for a limited period)
Commentary: Study Sheds Light on Stopping and Resuming DOACs in Afib Patients Undergoing Surgery – NEJM Journal Watch (free)
“The DOAC regimens were omitted for 1 day before a low–bleeding-risk procedure and 2 days before a high–bleeding-risk procedure. The DOAC regimens were resumed 1 day after a low–bleeding-risk procedure and 2 to 3 days after a high–bleeding-risk procedure.”
Related Commentary on Twitter
PAUSE is the largest trial to date that addresses perioperative DOAC timing and demonstrates safe management with the ability to influence guidelines https://t.co/WDM3yWt9nA
— JAMA Internal Medicine (@JAMAInternalMed) August 5, 2019
Potential Savings from Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers
6 Aug, 2019 | 08:06h | UTCPotential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers – JAMA Internal Medicine (free for a limited period)
“By maximizing generic substitution and therapeutic interchange, Medicare could have saved approximately $676 million (89.6%) in 2016 and 2017 of the total $754 million spent on these brand-name ACEIs and ARBs during those 2 years”.
Randomized Trial: Antihypertensive Regimens Compared for the Management of Severe Hypertension in Pregnancy
5 Aug, 2019 | 02:27h | UTCCommentary: Oral regimen management of acute hypertension in pregnancy – The Lancet (free)
Related Commentary on Twitter
NEW Research—Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe #hypertension in #pregnancy: an open-label, randomised controlled trial https://t.co/1Q2zspn7xf pic.twitter.com/cjzOG8KGOi
— The Lancet (@TheLancet) August 2, 2019
Perspective: If You Smoke Pot, Your Anesthesiologist Needs To Know
5 Aug, 2019 | 02:07h | UTCIf You Smoke Pot, Your Anesthesiologist Needs To Know – Kaiser Health News (free)
Related: Perioperative care of cannabis users: A comprehensive review of pharmacological and anesthetic considerations – Journal of Clinical Anesthesia (free)
“One small study of Colorado patients published in May found marijuana users required more than triple the amount of one common sedation medicine, propofol, as did nonusers.”
Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure
2 Aug, 2019 | 00:16h | UTC